Aardvark Therapeutics gains Rare Pediatric Disease Designation for Prader-Willi Syndrome
The FDA has granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare...
top of page
Browse by category
Search
Aardvark reveals positive data for ARD-101 in treating obesity or other metabolic conditions
Aardvark Therapeutics has reported positive clinical data from three Phase II trials for its lead product ARD-101, an oral small molecule...
Three trials to assess ARD-101 including for refractory weight gain post-bariatric surgery
Enrolment has begun in three Phase 2 studies of ARD-101, a first-in-class small molecule bitter taste receptor (TAS2R) pan-agonist. Two...
Browse by tag
bottom of page